Ausgabe 5/2011
Inhalt (32 Artikel)
Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
Ji Hye Min, Ho Yun Lee, Hoyeong Lim, Myung-Ju Ahn, Keunchil Park, Man Pyo Chung, Kyung Soo Lee
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
Keith T. Flaherty, Chetan Lathia, Reginald F. Frye, Lynn Schuchter, Maryann Redlinger, Mark Rosen, Peter J. O’Dwyer
Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
Lakshmi Rajdev, Abdissa Negassa, Qun Dai, Gary Goldberg, Kathy Miller, Joseph A. Sparano
The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats
V. Ashutosh Rao, Jun Zhang, Sarah R. Klein, Parvaneh Espandiari, Alan Knapton, Jennifer S. Dickey, Eugene Herman, Emily B. Shacter
Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma
Martha Romero, Josette Brière, Cédric de Bazelaire, Christophe Lebœuf, Li Wang, Philippe Ratajczak, David Sibon, Eric de Kerviler, Catherine Thieblemont, Anne Janin
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea
Bret Bannerman, Ling Xu, Matthew Jones, Christopher Tsu, Jie Yu, Paul Hales, Johan Monbaliu, Paul Fleming, Lawrence Dick, Mark Manfredi, Christopher Claiborne, Joseph Bolen, Erik Kupperman, Allison Berger
Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia
Meryem Albayrak, Uljan Konyssova, Zuhre Kaya, Turkiz Gursel, Sezen Guntekin, E. Ferda Percin, Ulker Kocak
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells
Davide Staedler, Elita Idrizi, Blanka Halamoda Kenzaoui, Lucienne Juillerat-Jeanneret
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
Uwe Pelzer, Dirk Arnold, Peter Reitzig, Julia Herrenberger, Friedrich Wilhelm Korsten, Manfred Kindler, Jens Stieler, Bernd Dörken, Hanno Riess, Helmut Oettle
Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein
Howard R. Mellor, Richard Callaghan
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases
Romain Guilhaumou, Nicolas Simon, Sylvie Quaranta, Arnauld Verschuur, Bruno Lacarelle, Nicolas Andre, Caroline Solas
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
Jianguo Zhi, Eric Chen, Pierre Major, Ivon Burns, Bridget Robinson, Joe McKendrick, Karen Rittweger, Markus Abt, David Goldstein
Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
Alfonso De Stefano, Chiara Carlomagno, Stefano Pepe, Roberto Bianco, Sabino De Placido
Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer
Mitsugu Kochi, Wataru Ichikawa, Eiji Meguro, Hiroyuki Shibata, Takuji Fukui, Michitaka Nagase, Yutaka Hoshino, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
Claudia Lebedinsky, Javier Gómez, Youn C. Park, Antonio Nieto, Arturo Soto-Matos, Trilok Parekh, Vicente Alfaro, Elena Roy, Pilar Lardelli, Carmen Kahatt
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
George R. Simon, Robert L. Ilaria Jr., Mika A. Sovak, Charles C. Williams, Eric B. Haura, Ann L. Cleverly, Amanda K. Sykes, Margaret M. Wagner, Dinesh P. de Alwis, Christopher A. Slapak, Mary A. Miller, David R. Spriggs
A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy
Tashinga E. Bapiro, Frances M. Richards, Mae A. Goldgraben, Kenneth P. Olive, Basetti Madhu, Kristopher K. Frese, Natalie Cook, Michael A. Jacobetz, Donna-Michelle Smith, David A. Tuveson, John R. Griffiths, Duncan I. Jodrell
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer
William C. Zamboni, Austin J. Combest, Julie A. DeLoia, Robert P. Edwards, Arlene S. Bridges, Beth A. Zamboni, Christine M. Walko, Angela Y. C. Yu, Thomas C. Krivak, Joseph L. Kelley
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
In Hae Park, Yeon-Su Lee, Keun Seok Lee, Sook-young Kim, Seung-Hyun Hong, Jaeheon Jeong, Hyewon Lee, Jungsil Ro, Byung-Ho Nam
Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival
Austin M. Guo, Xiuli Liu, Zaid Al-Wahab, Krishna Rao Maddippati, Rouba Ali-Fehmi, A. Guillermo Scicli, Adnan R. Munkarah
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Jeong Eun Kim, Baek-Yeol Ryoo, Min-Hee Ryu, Heung-Moon Chang, Dong Jin Suh, Han Chu Lee, Young-Suk Lim, Kang Mo Kim, Yoon-Koo Kang
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
Hernan Carol, Ingrid Boehm, C. Patrick Reynolds, Min H. Kang, John M. Maris, Christopher L. Morton, Richard Gorlick, E. Anders Kolb, Stephen T. Keir, Jianrong Wu, Amy E. Wozniak, Yu Yang, Mark Manfredi, Jeffrey Ecsedy, Jianmin Wang, Geoffrey Neale, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
N. Cézé, G. Thibault, G. Goujon, J. Viguier, H. Watier, E. Dorval, T. Lecomte
Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells
Ying-Wei Li, Guo-Yuan Zhu, Xiao-Ling Shen, Jian-Hong Chu, Zhi-Ling Yu, Wang-Fun Fong
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases
Masako Asayama, Nozomu Fuse, Takayuki Yoshino, Tomonori Yano, Makoto Tahara, Toshihiko Doi, Satoshi Fujii, Atsushi Ohtsu
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
Paul K. Paik, Leonard P. James, Gregory J. Riely, Christopher G. Azzoli, Vincent A. Miller, Kenneth K. Ng, Camelia S. Sima, Robert T. Heelan, Mark G. Kris, Erin Moore, Naiyer A. Rizvi
Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants
Velia D’Angelo, Maria Ramaglia, Adriana Iannotta, Stefania Crisci, Paolo Indolfi, Matteo Francese, Maria Carmen Affinita, Giulia Pecoraro, Addolorata Napolitano, Claudia Fusco, Matilde Oreste, Cristiana Indolfi, Fiorina Casale
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy
S. Pignata, F. Amant, G. Scambia, R. Sorio, E. Breda, W. Rasch, K. Hernes, C. Pisano, K. Leunen, D. Lorusso, L. Cannella, I. Vergote
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
E. Giorgio, C. Caroti, F. Mattioli, V. Uliana, M. I. Parodi, Mauro D’Amico, C. Fucile, V. Marini, F. Forzano, G. Cassola, A. Martelli, F. Faravelli, E. Di Maria
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
Juliette Thariat, Marie-Christine Etienne-Grimaldi, Vincent Launay-Vacher, Arturo Soto-Matos, Carlos Fernandez-Teruel, Thomas Ghafari, Pierre-Yves Marcy, Gérard Milano, Nicole Renée, Lauris Gastaud, Antoine Thyss
MTHFR 677TT genotype and toxicity of methotrexate: controversial results
Elixabet Lopez–Lopez, Javier Ballesteros, Africa Garcia-Orad